company background image
SBTX

Silverback Therapeutics NasdaqGM:SBTX Stock Report

Last Price

US$5.35

Market Cap

US$189.7m

7D

12.6%

1Y

-49.3%

Updated

28 Sep, 2022

Data

Company Financials +
SBTX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

SBTX Stock Overview

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases.

Silverback Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Silverback Therapeutics
Historical stock prices
Current Share PriceUS$5.35
52 Week HighUS$11.85
52 Week LowUS$2.80
Beta0
1 Month Change3.68%
3 Month Change26.18%
1 Year Change-49.29%
3 Year Changen/a
5 Year Changen/a
Change since IPO-78.60%

Recent News & Updates

Shareholder Returns

SBTXUS BiotechsUS Market
7D12.6%2.9%-2.0%
1Y-49.3%-24.2%-20.3%

Return vs Industry: SBTX underperformed the US Biotechs industry which returned -27.4% over the past year.

Return vs Market: SBTX underperformed the US Market which returned -22.1% over the past year.

Price Volatility

Is SBTX's price volatile compared to industry and market?
SBTX volatility
SBTX Average Weekly Movement8.0%
Biotechs Industry Average Movement11.1%
Market Average Movement6.9%
10% most volatile stocks in US Market15.8%
10% least volatile stocks in US Market2.8%

Stable Share Price: SBTX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: SBTX's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201692Laura Shawverhttps://www.silverbacktx.com

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Silverback Therapeutics Fundamentals Summary

How do Silverback Therapeutics's earnings and revenue compare to its market cap?
SBTX fundamental statistics
Market CapUS$189.69m
Earnings (TTM)-US$90.50m
Revenue (TTM)n/a

0.0x

P/S Ratio

-2.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SBTX income statement (TTM)
RevenueUS$0
Cost of Revenue-US$3.18m
Gross ProfitUS$3.18m
Other ExpensesUS$93.68m
Earnings-US$90.50m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.55
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did SBTX perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is SBTX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SBTX?

Other financial metrics that can be useful for relative valuation.

SBTX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does SBTX's PB Ratio compare to its peers?

SBTX PB Ratio vs Peers
The above table shows the PB ratio for SBTX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average1x
VOR Vor Biopharma
0.9x-7.8%US$162.1m
AKUS Akouos
1x31.4%US$198.9m
SVRA Savara
1.4x58.1%US$174.5m
GRCL Gracell Biotechnologies
0.8x-8.5%US$171.2m
SBTX Silverback Therapeutics
0.7x120.9%US$189.7m

Price-To-Book vs Peers: SBTX is good value based on its Price-To-Book Ratio (0.7x) compared to the peer average (1x).


Price to Earnings Ratio vs Industry

How does SBTX's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: SBTX is good value based on its Price-To-Book Ratio (0.7x) compared to the US Biotechs industry average (1.6x)


Price to Book Ratio vs Fair Ratio

What is SBTX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SBTX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.7x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate SBTX's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of SBTX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SBTX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SBTX's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Silverback Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


120.9%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SBTX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SBTX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SBTX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if SBTX's revenue is forecast to grow faster than the US market.

High Growth Revenue: SBTX is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SBTX's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Silverback Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-45.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: SBTX is currently unprofitable.

Growing Profit Margin: SBTX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SBTX is unprofitable, and losses have increased over the past 5 years at a rate of 45.8% per year.

Accelerating Growth: Unable to compare SBTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SBTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).


Return on Equity

High ROE: SBTX has a negative Return on Equity (-32.35%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Silverback Therapeutics's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: SBTX's short term assets ($263.1M) exceed its short term liabilities ($11.1M).

Long Term Liabilities: SBTX's short term assets ($263.1M) exceed its long term liabilities ($4.1M).


Debt to Equity History and Analysis

Debt Level: SBTX is debt free.

Reducing Debt: SBTX had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SBTX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: SBTX has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of 42.8% each year.


Discover healthy companies

Dividend

What is Silverback Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Silverback Therapeutics Dividend Yield vs Market
How does Silverback Therapeutics dividend yield compare to the market?
SegmentDividend Yield
Company (Silverback Therapeutics)n/a
Market Bottom 25% (US)1.6%
Market Top 25% (US)4.6%
Industry Average (Biotechs)2.7%
Analyst forecast in 3 Years (Silverback Therapeutics)0%

Notable Dividend: Unable to evaluate SBTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SBTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SBTX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SBTX's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as SBTX has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure


CEO

Laura Shawver (64 yo)

2.42yrs

Tenure

US$821,500

Compensation

Dr. Laura K. Shawver, Ph D., serves as Independent Director of Bright Peak Therapeutics AG since June 2021. She serves as Chief Executive Officer and Director of Silverback Therapeutics, Inc. since joining...


CEO Compensation Analysis

Laura Shawver's Compensation vs Silverback Therapeutics Earnings
How has Laura Shawver's remuneration changed compared to Silverback Therapeutics's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a

-US$91m

Mar 31 2022n/an/a

-US$96m

Dec 31 2021US$822kUS$530k

-US$90m

Sep 30 2021n/an/a

-US$79m

Jun 30 2021n/an/a

-US$65m

Mar 31 2021n/an/a

-US$47m

Dec 31 2020US$14mUS$325k

-US$33m

Compensation vs Market: Laura's total compensation ($USD821.50K) is below average for companies of similar size in the US market ($USD1.69M).

Compensation vs Earnings: Laura's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: SBTX's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Members

Experienced Board: SBTX's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

NasdaqGM:SBTX Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
15 Nov 21BuyUS$36,048Jonathan RootIndividual2,364US$52.07

Ownership Breakdown

What is the ownership structure of SBTX?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders449,3661.3%
Hedge Funds1,906,6185.4%
General Public8,544,29424.1%
VC/PE Firms10,650,91630.0%
Institutions13,905,02839.2%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 25 shareholders own 70.93% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
24.65%
OrbiMed Advisors LLC
8,740,887$46.8m0%0.72%
10.49%
FMR LLC
3,718,374$19.9m-1.97%no data
5.39%
Nextech Invest Ltd.
1,910,029$10.2m0%3.02%
5.38%
K2 & Associates Investment Management Inc.
1,906,618$10.2m23.67%1.68%
3.91%
Nantahala Capital Management, LLC
1,386,138$7.4m51.72%0.58%
2.98%
The Vanguard Group, Inc.
1,056,664$5.7m28.35%no data
2.78%
Rubric Capital Management LP
986,453$5.3m0%0.25%
2%
BlackRock, Inc.
707,845$3.8m-55.97%no data
1.62%
EcoR1 Capital, LLC
575,359$3.1m74.6%0.09%
1.55%
Renaissance Technologies LLC
549,299$2.9m-18.08%no data
1.28%
Millennium Management LLC
455,051$2.4m0%no data
1.2%
Two Sigma Advisers, LP
426,700$2.3m15.08%0.01%
0.96%
Prosight Management, LP
341,108$1.8m4.84%1.18%
0.9%
Oasis Management Company Ltd.
317,662$1.7m0%0.13%
0.69%
Bank of America Corporation, Asset Management Arm
243,441$1.3m-7.74%no data
0.65%
Citadel Advisors LLC
231,666$1.2m18.71%no data
0.63%
Geode Capital Management, LLC
223,652$1.2m-38.33%no data
0.59%
Silverarc Capital Management, LLC
209,108$1.1m0%0.45%
0.55%
Two Sigma Investments, LP
193,500$1.0m-51.77%no data
0.54%
Morgan Stanley, Investment Banking and Brokerage Investments
190,095$1.0m-50.71%no data
0.48%
Affinity Asset Advisors, LLC
170,000$909.5k0%0.52%
0.47%
T. Rowe Price Group, Inc.
166,200$889.2k-44.71%no data
0.45%
Laura Shawver
158,635$848.7k98.55%no data
0.43%
Susquehanna International Group, LLP, Asset Management Arm
151,582$811.0k0%no data
0.37%
New York Life Investment Management LLC
132,860$710.8k17.06%no data

Company Information

Silverback Therapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Silverback Therapeutics, Inc.
  • Ticker: SBTX
  • Exchange: NasdaqGM
  • Founded: 2016
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$189.691m
  • Shares outstanding: 35.46m
  • Website: https://www.silverbacktx.com

Number of Employees


Location

  • Silverback Therapeutics, Inc.
  • 500 Fairview Avenue North
  • Suite 600
  • Seattle
  • Washington
  • 98109
  • United States


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SBTXNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDDec 2020

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/28 00:00
End of Day Share Price2022/09/28 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.